Close Menu

NEW YORK – T2 Biosystems on Tuesday said that its preliminary first quarter revenues are expected to grow 22 to 44 percent year over year.

Due to the coronavirus pandemic, it also said that it will suspend its 2020 guidance, while adding it has licensed a SARS-CoV-2 test to be adapted to its rapid diagnostics platform.

For the quarter ending March 31, T2 estimates first quarter total revenue will be in the range of $2.2 million to $2.6 million compared to $1.8 million for the first quarter of 2019. The consensus Wall Street revenue estimate for Q1 is $3.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
13
Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.